ῌ*2a9b
50
» 2009
ῑ῍
ῌ῏
Rothia mucilaginosa
(Stomatococcus mucilaginosus) 1 1), 2)1)3) !4)"5)
#1)$ %1)&1) 1)1)
' (!1)) *"6)+,-3)#7)$% &1), 7)
1)
.'
2)
+4/565
/
()01*23(
3)
=0
4)
CD2
5)
+4
/
(301EFB<(
6)
.'
/
(4!5
7)
.'
/
(*23/
1/
1,789
:;59-.<3
:;5>9/1<
/
?@A-B<
/
1*23(
G5H 21 6 10 I 9 J)K 5H 21 6 12 I 14 J7L
Rothia mucilaginosa MNOPQ 1 RSTK UEFVW
8\
9\]^EF_`a]
mucilaginosa
hY
b c[c[MK :
XYZ[
efghib M 68 jK <b k=l
em-hK n?]opqr
T R. mucilaginosa a
~[ib MH
awxK †
‹XY hib PMIC/ID-35
~[ib PC.6.1B RM
}G
F3
I€‚ƒ)B~[YX
GPMIC/ID-35, PC.6.1B, GPI ‡‚K API STAPH,
N-ID ˆ‰ SP-18L eKXY
API Coryne, rapid ID 32 STREP
[ib Ž
>Š
GPI ‡‚RMI€‚ƒ)B~[Y
TK &Œ
L RSTK M 5 RMMyz{Ia
awxK MN
O8’“eP”UEF•–
>
6s\NOteu@hYXib CPFX
AB eCK vDEwxyz{pethK | F
]X„ƒJX
K
XY;d]X R.
S
XM
~
L a~[YXi‘ ƒSTK NO
XYMEF_`—‹ahYQ˜Š
RSƒS
a™
šx[ib
K K opqr
Key words: Rothia mucilaginosa, Stomatococcus,
῎
ῐ
Rothia mucilaginosa MN Stomatococcus mucilaginosus ahYTx[K ›NO
PQŠ
œU
Vœyz{pRS
1)
EFahYUEFVW
ž8\K 8\
]w2£5)K
~[
b [ZR :
aMƒyz{F¤
€§¨©WXªŠ
\–]^µ¶ (·181῍8611) +4_¸`¹ 6῍20῍2
.' / ()01*23(
TEL: 0422῍47῍5511 Gº 2824L
FAX: 0422῍47῍5651
E-mail: [email protected]
50 *2a9b
¼½ Vol. 20
No. 1
2010.
K
9\]^;dƒŸ
R¡¢
;dM]Xb
¥¦¢
Coagulase-Negative
Staphylococci (CNS) ]^Myz{«‚¬p
4)

b
~[YXi
”
ƒZ¯K 3°
²³
aƒ—`RS
a­
~[
MEFA`ahYY®
H
XYKXx[
X¯‹w±[
RMK €‚ƒ)B~[YX]Xi´
ƒL‘
RS
R. mucilaginosa 1 ()89<=>@A
51
lkMmnG 38.2 fodpq rfstu(
)vwxWy%] lkMz@{
R. mucilaginosa |}~ 1 01 WBC7200/ml (Blast 91.5€) $
‚,ƒ„d
!"#$% &'()*
'+,-./01$$2
341
536789:;()89<=>89
CRP 11.4 mg/dl $
‰]uŠ‹dŒih
 ŽG l k M q cefepime (CFPM) 1 g 
?@
2/day 
ABCD1
†‡ˆpq
d \ 2006 Y 12 Z 27 ‘ ’ h
Gemtuzumab ozogamicin d“”•
E
FG 68 H I
–—•hƒ„
†d˜\ 2007 Y 1
Z 5 ‘ Staphylococcus haemolyticus JKG LMNOPQ RS TUVW
XG 2005 Y 2 Z
vancomycin (VCM) 1 g2/day ()
meropenem (MEPM) 0.5 g2/day ™
]
[\ ]^_`abc$,^d
šd\ co‡ˆd›]i 2007 Y 1
2006 Y 2 Ze
ef[\ bc
Z 21 ‘q ciprofloxacin (CPFX) 300 mg2/day
gh,]i 2006 Y 12 Z+Bjk
œ 28 ‘qv CPFX 200 mg3/day ž
lk$,^
$Ÿ
$¡¢8Z 31 ‘e)oŒi 8
‘£¤•z¥
 1.
z@{
RBC
Hb
Ht
WBC
Blast
Seg
Lym
Mono
Plt
® 1.
lkMz@{mn
¸
324104/ml
10.3 g/dl
29.2€
7,200/ml
91.5€
0€
8.0€
0.5€
4.4104/ml
2/day () CFPM 2 g2/day šd“”
¹@{
TP
ALB
AST
ALT
ALP
LDH
UN
Cr
CRP
2 ¦=> 4 §>¨1©%’
h R. mucilaginosa d*• ef VCM 1 g
• ‡ª« 2007 Y 2 Z 7 ‘¬k
6.9 g/dl
3.6 g/dl
41 IU/L
47 IU/L
354 IU/L
200 IU/L
18.4 mg/dl
0.7 mg/dl
11.4 mg/dl
$,^ ­® 1¯
1)
z¥
’h*• R. mucilaginosa
*° 89@{ ­5389<=>89
@A±²¯ () ³´µ
?
¶·¶
Ž
G.O: gemtuzumab ozogamicin, CFPM: cefepime, MEPM: meropenem, CPFX: ciprofloxacin, GM:
gentamicin, VCM: vancomycin
‘
º¹»¼½ Vol. 20
No. 1
2010. 51
&¸´w¹
52
2) Bauer ‹Œ$ SN Ž
BacT/ALERT 3D
Er
BacT/ALERT SN BacT/ALERT SA !"#
$
%&'() *+
,-./012
"34
BacT/ALERT SN 56
*+&789
:;& M58 :;< =>?@ ABCDE
II :;& ABCDE:;<
BCP
F MS-CFX/
BD GHIJK
:;& MS-CFX/IJK
<
5) E
18 NO *+&
1) !
$
Z 35[`a RS :;Z
cdA e?@fgJ <
k BD Phoenix BD
BD mHn
st
uE<
xEqr
svO
st
xEqr
NO 5\ NaCl HTDyJzE
yJ{E9BJTg
& (BHI; DIFCO) 12
| } ~ $  6 h i 2 j
rRNA PCR Z€
E
vJ
16 S
‚)M
ƒ„k$
hi
VCM, CFPM, MEPM, CPFX gentamicin
†‡"iˆH‰ŠE-E
7JJ:;& « 2.
52
,-./0Z
2) "#$%&'()*+
¡]^_
24
¢Z
KE
:;ABC
¥0
N O Kirbyῌ
« 2 72
CgKE
No. 1
2010.
.E
¦#$ Cg
¡ba¢Z
RS :;&Q
"3:;ABCDE:;
&Qn!Z¬ P MS-CFX/IJK
:
;&Z2 | ­®5
3) BD Phoenix k Z R. mucilaginosa
k4" 99\ n#k¯ mH
²" st
xEqr
Z
°±o
²"
|²"Z¬ P
16S rRNA ³$´Mƒ‚ R. mucilagiMƒnµ¶$
nosa
4)
2
†‡"iˆ
(A) Rothia mucilaginosa CgKE 789:;& ]^_
&QZ© ª" ­·
'º(»)@¼½ Vol. 20
0
"3 1.5
§2¨ &QZ© ª"#$
5\ NaCl H BHI Tg
penicillin G (PCG), oxacillin (MPIPC),
(GM) ,-."TudŸ24
p-Eqr
4)
"56
mm ¤
PMIC/ID-35 cl SP-
˜™t
DE:;&Q£1CgKE
35[ba
gE.wst
N-ID r
8t
š›‹œ
ž
A
 GPI oEu VITEK 1 NO
ABCDE:;Z 35[ 5\]^_
$op-Eqr
J
STREP —Q
:;< VO W$ XY:;
hi2j
VITEK 2 API STAPH, API Coryne, rapid ID 32
4
3) hi2j•– PMIC/ID-35 cl PC.6.1B c
l QR &HS HK TU- RS :;& RS
bac
‘’
“ MIC ”k$
LM EX
P BacT/ALERT SA 56
MF-CFX/IJK
NO )hi
24
°±% 2 # SN
¡ (B) 789:;
R. mucilaginosa 3QN 1 +
MPIPC
CPFX 28 mm CFPM, MPIPC
E !"
PMIC/ID-35
GPI - . / (VITEK 2)
,3, 4, 913) Z[
\]^
ijY6 &de$%fg
R.
567
34./
56
$27'*tuvw.+$xyY67*
3, 10) 2002 (z 56){|T`Ja
+ A
bNUV
\}3~"€/=€l
39$27‚ƒ567
67*
N+
14)
ˆ,ab
Rothia mucilaginosa A¨©3¡B Lº
?
3.
SN E !"
(mm)
MIC ( mg/ml)
28
0
19
22
15
0
20
0.25
4
4
1
4
#32
0.5
Y67
‘
:;"
~"¬R
4./
4./
:
PMIC/ID-35
PC.6.1B
GPI -./
GPI -./
API STAPH
API Coryne
BD Phoenix
Walk Away96
VITEK 1
VITEK 2
"¶
"¶
¯2
102202000
50200000000
¯2
2302130
7450121
°
²
²
°
²
²
rapid ID 32
STREP
N-ID !"
SP-18
"¶
20023101100
²
"¶
532464
²
R.
\LMNqs
, „*?
5
*7&LMN†`J‡
„#‰Š‹
de$ŒQ
, de$-.Ž/+
’*& 3de$YQ'k
“028 ?”•56 H€/=€l
2002 (–— LMNt˜
2 $ 2 7 › d CPFX
clavulanate AœžB 3"4
14)
\™š1
amoxicillin-
Ÿ
22Y Ei# YO
567*
`JabN
U V 5 6 R. mucilaginosa 7 8 3 ¡ 0 h CPFX, ofloxacin
levofloxacin u¢£m:
¤ml¥}3 MIC Rothia mucilaginosa A¨©3¡B 0hª
R. mucilagi-
nosa Q'k"=lmn.oplqXhrs
mucilaginosa `JabN
Penicillin G
Oxacillin
Cefepime
Meropenem
Gentamicin
Ciprofloxacin
Vancomycin
!_"
<=>?3
56 1 :;"
}3
PQRSTUVW*X$Y67
3B
2.
!"=H
'#`JabNcde$%fgNhX$
7** 6 :;" 5 :;"
@$
IJKJ3+1) 3LMNO
8 + 9
<=>? C +,
D? 4E<=.F!"G?
GM 4 mg/ml + ,
mucilaginosa 01234./
,
53
R. mucilaginosa
0.25 mg/ml $%&*+
5) :;">
15
CPFX MIC #32 mg/ml $%&'( )*
PCG MIC
:;""*
3
Rothia mucilaginosa
§H6³€£w€´
Streptococcus acidominimus
Rothia mucilaginosa
Kocuria kristinae
Cellulomonas spp./
Microbacterium spp.
Rothia dentocariosa
Streptococcus pneumoniae/
Streptococcus oralis
Staphylococcus warneri B
¦§V56783¡
­;
(®)
«]^9?K
PYRῌ LAPῌ ESCῌ
97
99
99
56
44
99
±
±
µ
±
N
±
±
N
N
±
N
N
±
µ
±
N
N
±
±
N
N
99
N
N
N
99
°· +, ²· 2
±· ? µ· G? N· Ž¸<2
ῌ· 3@
h¹=*«]^9Ž¸<
PYR: pyrrolidonyl arylamidase activity, LAP: leucine aminopeptidase, ESC: esculin hydrolysis
?@»A«B^¼½ Vol. 20
No. 1
2010. 53
.·¸¹º
54
16 15) #$% CPFX &
()*
+,-.
'"
!"<=>?@A?BC
DEF'
N&O'
R
2)
9:;!
GH IJ=(KLM
S TUVU
WXYZ[\ ]^V_`[
\&
ῌ
1)
01 234
PQ1 ῍
!" CPFX /"
56 &0" 78
!"
3)
ab
1 CNS cUWXVde6 fg
Lhij
&k!(
!1lV!lm
Staphylococcus, Micrococcus
"opq=
#n Streptococcus rs'"!R
4)
&!56
"!3, 4, 6) tuY 8 vs@wJ
\ x v s y h z & J{
'"!1
#n GPI fhz (VITEK 2) 2 @w
PMIC/ID-35
0 &0" syhz&
"!V!@wJ|"!YZ}
laginosa rs
5)
'
1 R. muci-
!1s'R
6)
&~' s@wJ|"!Y
Z}
!"1 d"ῌKLM
῍GH€
N
#n‚yphJ€ƒ„;
y?†h‡ˆ ῎fgLhi‰ŠJk
y‹KLhi‰ŠJŒ

&
Staphylococcus o
+, ”
ῐ5 NaCl ŽŒ
8)
OYZ"ῌ>@’
7)
• ῍–—z†=‹’=‹˜“hi
• ῎?™’B‹˜Aš›“hi+, ”
•
eYZ[\
8) syhz&
'"!V!
s@wJ
J&
d(1
• ῏œŠ—Bež#Ÿ ”
&
7)
#n Micrococcus o!‘
"&R
“hi‰ŠJ ”Œ
῏
9)
!" YZ¡ ¢£@w
”$ 3• -.e%#
vs&R
YZ}&¤¥'
10)
(V&
!"v¦OVs[\
l1 §"s@wJvsyhz
&
'&(¨!56
tD )
!" R. mucilaginosa Y©ª«
O* 78+
¬ R. mucilaginosa
­®¯° GH(Y©,±
@A?BC
V¶Z&
11)
#n<=>?
²-V³)!"´µX
ab
54 &/»0­1W¼½ Vol. 20
No. 1
2010.
12)
Bergan, T., M. Kocur. 1982. Stomatococcus mucilaginosus gen. nov., sp. Nov., ep. Rev., a member
of the family Micrococcaceae. Int. J. Syst. Bacteriol. 32: 374ῌ377.
Abraham, J., S. Bilgrami, D. Dorsky, R. L. Edwards, et al. 1997. Stomatococcus mucilaginosus
meningitis in a patient with multiple myeloma
following autologous stem cell transplantation.
Bone Marrow Transplantation 19: 639ῌ641.
Treviño, M., A. Garcı́a-Zabarte, A. Quintás, et al.
1998. Stomatococcus mucilaginosus septicemia
in a patient with acute lymphoblastic leukaemia. Eur. J. Clin. Microbiol. Infect. Dis. 17: 505ῌ
507.
Fanourgiakis, P., A. Georgala, M. Vekemans, et
al. 2003. Bacteremia due to Stomatococcus mucilaginosus in neutropenic patients in the setting
of a cancer institute. Clin. Microbiol. Infect. 9:
1068ῌ1072.
Korsholm, T. L., V. Kaakr, J. Prag. 2007. Eight
cases of lower respiratory tract infection
caused by Stomatococcus mucilaginosus. Scand.
J. Infect. Dis. 39: 913ῌ917.
Rizvi, M., N. Fatima, I. Shukla, et al. 2008.
Stomatococcus mucilaginosus meningitis in a
healthy 2-month-old child. J. Med. Microbiol.
57: 382ῌ383.
Michels, F., J. Colaert, F. Gheysen, et al. 2007.
Late prosthetic joint infection due to Rothia
mucilaginosa. Acta Orthop. Belg. 73: 263ῌ267.
Ruo#, K. L. 2007. Aerococcus, abiotrophia, and
other aerobic catalase-negative, Gram-positive
cocci. p. 443ῌ454, In: Manual of clinical microbiology, 9th ed. (P. R. Murray, E. J. Baron, M. L.
Landry, et al. eds.), American Society for Microbiology, Washington, D.C.
Granlund, M., M. Linderholm, M. Norgren, et al.
1996. Stomatococcus mucilaginosus septicemia
in leukemic patients. Clin. Microbiol. Infect. 2:
179ῌ185.
Gruson, D., G. Hilbert, A. Pigneux, et al. 1998.
Severe infection caused by Stomatococcus mucilaginosus in a neutropenic patient: Case report
and review of the literature. Hematol. Cell
Ther. 40: 167ῌ169.
Goldman, M., U. B. Chaudhary, A. Greist, et al.
1998. Central nervous system infections due to
Stomatococcus mucilaginosus in immunocompromised hosts. Clin. Infect. Dis. 27: 1241ῌ1246.
Paci, C., R. Franci, C. Casini, et al. 2000. Treatment of Stomatococcus mucilaginosus bloodstream infection in two acute leukemia patients, first reported at our cancer center. J.
Chemother. 12: 536ῌ537.
R. mucilaginosa 1 13)
14)
Lee, A. B., P. Harker-Murray, P. Ferrieri, et al.
2008. Bacterial meningitis from Rothia mucilaginosa in patients with malignancy or undergoing hematopoietic stem cell transplantation.
Pediatr. Blood Cancer 50: 673ῌ676.
Hughes, W., D. Armstrong, G. P. Bodey, et al.
2002. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with can-
15)
55
cer. Clin. Infect. Dis. 34: 730ῌ751.
Ei#, C., G. Peters. 1998. In vitro activity of ciprofloxacin, ofloxacin, and levofloxacin against
Micrococcus species and Stomatococcus mucilaginosus isolated from healthy subjects and
neutropenic patients. Eur. J. Clin. Microbiol.
Infect. Dis. 17: 890ῌ892.
A Case of Rothia mucilaginosa (Stomatococcus mucilaginosus)
Bacteremia in a Patient with Acute Myelocytic Leukemia and Evaluation
of the Ability to Identify for This Organism Used Identification Kits
Yoko Fukugawa,1), 2) Mitsuhiro Okazaki,1) Kiyofumi Ohkusu,3) Hiroyuki Nishiyama,4)
Yoshimi Higurashi,5) Ayako Tanouchi,1) Takahiro Okuyama,1) Shota Yonetani,1)
Hiroshi Makino,1) Noriko Sawada,1) Koji Araki,1) Nobuyuki Takayama,6)
Takayuki Ezaki,3) Hiroaki Ohnishi,7) Takashi Watanabe1), 7)
1)
2)
3)
4)
5)
6)
7)
Laboratory of Medicine, Kyorin University School of Medicine
Department of Microbiology and Immunology, Graduate School of Health Care
Sciences, Tokyo Medical and Dental University
Department of Microbiology, Regeneration and Advanced Medical Science,
Gifu University Graduate School of Medicine
Central Clinical Laboratories, Surugadai Nihon University Hospital
Department of Infection Control and Prevention, University of Tokyo Hospital
Second Department of Internal Medicine, Kyorin University School of
Medicine
Department of Laboratory Medicine, Kyorin University School of Medicine
Rothia mucilaginosa is found in the oral cavity and pharynx of man where it forms part of the normal
microflora. This organism is also recognized as an opportunistic pathogen causing bacteremia, meningitis
and pneumoniae. We report the first case of bacteremia caused by R. mucilaginosa in Japan. A 68-year-old
male with acute myeloid leukemia received gemtuzumab ozogamicin therapy. The patient had signs of
oral mucositis, and R. mucilaginosa was isolated from blood cultures during prophylactic ciprofloxacin. We
also evaluated the ability of the following kits to identify R. mucilaginosa: PMIC/ID-35, PC.6.1B, GPI card,
API STAPH, API Coryne, rapid ID 32 STREP and N-IDtestSP-18. PMIC/ID-35 and GPI card could identify
this organism, because they had its bacterial code. PC.6.1B could not identify it, and another kit
misidentified it as other gram positive organisms. This study illustrates the possible virulence of R.
mucilaginosa in immunocompromised host with oral mucositis, and indicates that this organism may be
misidentified in the currently used commercial kits.
Vol. 20
No. 1
2010. 55